Regulatory Approval

RNS Number:8113W
Maelor PLC
23 March 2004

23 March 2004

                 Maelor Receives Volplex(R) Regulatory Approval


Wrexham, UK: Maelor plc, the specialist healthcare products company, announces
that it has received approval from the UK Medicines and Healthcare products
Regulatory Agency (MHRA) to launch a 1 litre version of its blood plasma
substitute Volplex.  Availability through its UK distributor, Cambridge
Laboratories, is expected shortly.

The 1 litre Volplex product wasdeveloped in response to the needs of customers
and patients and complements the existing 500ml size.  As the dose of Volplex
given to a patient is often in excess of 1 litre, the larger size is aimed at
reducing the workload of overstretched medical staff.

Since its launch in 2002 Volplex has established itself in the #9m UK market by
winning several major contracts. In addition, Volplex has expanded its
international franchise by gaining regulatory approval in Argentina in December
2003, where it will be sold by Ahimsa SA. Distribution agreements have also been
established in South Africa and Bangladesh (where regulatory applications have
already been submitted) and in China and Australia in preparation for future
launches in those markets.

Stephen Appelbee, Chief Executive of Maelor, said:

"Volplex has received a strong reception since launch.  Having announced the 1
litre development programme in our last Annual Report, we are pleased to see it
completed within a year.  Wethink that the approval of this new Volplex
presentation, combined with increasing global concerns about blood supplies,
will enhance the product's growth prospects both in the UK and worldwide. We
also anticipate that the new version will allow Maelor to increase margins on
Volplex in the medium term."


Further information:

Maelor plc
Stephen Appelbee, Chief Executive Officer              01978 810 153

Financial Dynamics
Ben Atwell/Lucy Briggs                                 020 78313113


Notes to editors:

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia(lower than normal
blood volume).


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
REAEAXDAASSLEFE